• Erin Duffy, Chief of R&D, Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator – CARB-X (USA)
  • Laura Marin, Head, Joint Programming Initiative on Antimicrobial Resistance – JPIAMR (Sweden)
  • Peter Beyer, Deputy Executive Director, Global Antibiotic Research & Development Partnership – GARDP (Switzerland)


  • Herman Goossens, Emeritus Professor of Medical Microbiology at the University of Antwerp (Belgium) and Chair of the Scientific Advisory Committee of GARDP

Presentation 1: CARB-X: building and sustaining an early-development pipeline of high-impact products to prevent, diagnose and treat bacterial infections (Erin Duffy)

  • Non-dilutive funding and comprehensive support model
  • Focus is Hit-to-Lead through demonstration of safety in human clinical studies
  • Portfolio of 93 projects across therapeutics, preventatives and rapid diagnostics

Presentation 2: The JPI-AMR funding model and overview of projects funded in the Therapeutics Pillar (Laura Marin)

  • The funding model; international consortia
  • The discovery pipeline; the lead generation landscape
  • Project portfolio overview across therapeutics, alternatives and diagnostics

Presentation 3: GARDP: a non-profit R&D and access organization (Peter Beyer)

This live webinar including an interactive Q&A session was broadcast on 22 January 2024.

If you have questions or comments, please let us know: revive@gardp.org.